Your browser is no longer supported. Please, upgrade your browser.
Settings
DFFN Diffusion Pharmaceuticals Inc. daily Stock Chart
DFFN [NASD]
Diffusion Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-5.10 Insider Own0.10% Shs Outstand4.68M Perf Week19.02%
Market Cap10.25M Forward P/E- EPS next Y-1.83 Insider Trans0.00% Shs Float4.59M Perf Month10.05%
Income-17.60M PEG- EPS next Q-0.61 Inst Own31.80% Short Float1.43% Perf Quarter-24.74%
Sales- P/S- EPS this Y-86.10% Inst Trans407.52% Short Ratio0.73 Perf Half Y-55.31%
Book/sh4.11 P/B0.53 EPS next Y29.10% ROA-91.40% Target Price10.00 Perf Year-66.82%
Cash/sh1.79 P/C1.22 EPS next 5Y- ROE-106.80% 52W Range1.83 - 11.00 Perf YTD10.05%
Dividend- P/FCF- EPS past 5Y43.90% ROI- 52W High-80.09% Beta0.08
Dividend %- Quick Ratio9.00 Sales past 5Y- Gross Margin- 52W Low19.67% ATR0.15
Employees10 Current Ratio9.00 Sales Q/Q- Oper. Margin- RSI (14)55.66 Volatility8.30% 8.00%
OptionableNo Debt/Eq0.00 EPS Q/Q30.40% Profit Margin- Rel Volume0.79 Prev Close2.03
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume89.37K Price2.19
Recom- SMA209.04% SMA501.98% SMA200-27.71% Volume70,456 Change7.88%
Mar-21-18Initiated H.C. Wainwright Buy $1.25
Sep-03-19 10:30AM  Diffusion Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire
Aug-15-19 10:15AM  DFFN: Positive Safety Data for Dose Escalation Portion of Phase 3 GBM Trial Zacks Small Cap Research
Aug-08-19 05:15PM  Diffusion Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Jul-23-19 08:30AM  Diffusion Pharmaceuticals Reports Favorable Safety Data for Dose-Escalation Run-in of Phase 3 INTACT Study in Glioblastoma Multiforme Patients GlobeNewswire
Jul-11-19 03:21PM  The Diffusion Pharmaceuticals (NASDAQ:DFFN) Share Price Is Down 98% So Some Shareholders Are Very Salty Simply Wall St.
May-28-19 04:05PM  Diffusion Pharmaceuticals Inc. Announces Closing of $6.45 Million Offering Priced At-the-Market GlobeNewswire
May-24-19 09:00AM  Diffusion Pharmaceuticals Inc. Announces $6.45 Million Registered Direct Offering & Private Placement GlobeNewswire -23.27%
May-23-19 07:30AM  Diffusion Pharmaceuticals Receives Notice of Intention to Grant a Patent Related to Use of TSC in Combination with tPA in Ischemic Stroke from European Patent Office GlobeNewswire
May-13-19 02:45PM  DFFN: Phase 2 Study of TSC in Stroke to Start in Summer 2019 Zacks Small Cap Research -7.44%
May-09-19 04:05PM  Diffusion Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Apr-17-19 10:00AM  DFFN: Data from Initial 8 Patients in Phase 3 GBM Trial Expected in mid-2019 Zacks Small Cap Research
Mar-20-19 09:00AM  Diffusion Pharmaceuticals Reports 2018 Financial Results and Provides Business Update GlobeNewswire
Mar-08-19 05:08PM  4 Stocks Join Ben Graham Net-Net Screener Friday GuruFocus.com -28.57%
Feb-11-19 04:00PM  Poster Presented at International Stroke Conference Describing Diffusions On-Ambulance Phase 2 Trial with TSC for Treating Acute Stroke GlobeNewswire -9.64%
Jan-22-19 01:55PM  How Does Investing In Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Impact The Volatility Of Your Portfolio? Simply Wall St. -6.11%
Jan-04-19 09:00AM  Diffusion Pharmaceuticals Chief Executive Officer David Kalergis to Present at 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire +12.06%
Jan-03-19 09:00AM  Diffusion Pharmaceuticals Executes Successful NASDAQ Compliance Plan: Company Will Remain Listed on NASDAQ Stock Market GlobeNewswire -5.24%
Dec-18-18 06:55AM  Today's Research Reports on Trending Tickers: Evofem Biosciences and Diffusion Pharmaceuticals ACCESSWIRE -19.50%
Dec-17-18 01:30PM  4 Stocks Providing Investor Opportunity Right Now ACCESSWIRE
09:55AM  U.S. Patent Office Awards Diffusion Exclusive Rights for Use of TSC in Conjunction with Only FDA-Approved Stroke Therapeutic GlobeNewswire
Dec-13-18 02:00PM  Diffusion Pharmaceuticals Announces 1-for-15 Reverse Stock Split As Part Of NASDAQ Compliance Plan GlobeNewswire -5.44%
Dec-10-18 10:15AM  DFFN: Phase 2 Clinical Trial of TSC in Acute Stroke to Commence in 2019 Zacks Small Cap Research -15.75%
Nov-15-18 09:15AM  Diffusion Pharmaceuticals Chief Scientific Officer Dr. John L. Gainer to Present at 2018 Annual Meeting of the Society for NeuroOncology GlobeNewswire
Nov-14-18 09:00AM  Diffusion Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Oct-15-18 12:00PM  Diffusion Pharmaceuticals Chief Financial Officer William Bill Hornung to Present at 2018 BIO Investor Forum GlobeNewswire
Sep-25-18 09:00AM  Diffusion Names William (Bill) Hornung Chief Financial Officer GlobeNewswire -9.96%
Sep-12-18 09:00AM  FDA Approves Start of Innovative On-Ambulance Phase 2 Clinical Trial for Treatment of Acute Stroke by Diffusion Pharmaceuticals GlobeNewswire +13.21%
Aug-29-18 08:00AM  Diffusion Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-16-18 02:00PM  DFFN: Enrollment Continues in Phase 3 Trial of TSC in GBM Zacks Small Cap Research -6.10%
Aug-13-18 08:30AM  Diffusion Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire +5.69%
Jun-12-18 08:30AM  Diffusion Pharmaceuticals Announces Validation of European Patent for Oral Formulations of TSC GlobeNewswire
May-29-18 01:04PM  CORRECTION: Diffusion Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
May-15-18 04:45PM  DFFN: Preparing for Phase 2 Clinical Trial of TSC in Acute Stroke Zacks Small Cap Research
May-10-18 04:05PM  Diffusion Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update GlobeNewswire -6.90%
Apr-19-18 04:45PM  DFFN: Enrollment in Phase 3 GBM Trial Continuing Zacks Small Cap Research
Apr-03-18 04:00PM  Diffusion Pharmaceuticals to Present at The MicroCap Conference ACCESSWIRE
07:30AM  Diffusion Pharmaceuticals Reports 2017 Financial Results and Provides Business Update GlobeNewswire
Feb-22-18 10:00AM  DFFN: Phase 3 GBM Trial Underway; Planning for Phase 2 Trial in Stroke Zacks Small Cap Research
Feb-06-18 04:00PM  Diffusion Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference GlobeNewswire
Feb-01-18 08:15AM  Diffusion Pharmaceuticals Announces Allowances of Two U.S. Patent Applications GlobeNewswire +6.56%
Jan-29-18 04:00PM  Diffusion Pharmaceuticals Announces First Patient Dosed in Phase 3 Trial with TSC in Inoperable Glioblastoma Multiforme GlobeNewswire
Jan-24-18 07:30AM  Abstract Outlining Pre-Hospital Stroke Study with Diffusion Pharmaceuticals TSC To Be Presented at the International Stroke Conference GlobeNewswire
Jan-18-18 01:54PM  Diffusion Pharmaceuticals Inc (DFFN): Shoring up the Balance Sheet by Selling Stock Comes with a Price SmarterAnalyst -35.63%
06:00AM  Diffusion Pharmaceuticals Announces $12 Million Underwritten Public Offering GlobeNewswire
Jan-10-18 08:00AM  Todays Research Reports on Stocks to Watch: Diffusion Pharmaceuticals and Pain Therapeutics ACCESSWIRE -13.88%
Jan-03-18 08:00AM  Diffusion Pharmaceuticals to Present at the 10th Annual Biotech Showcase Conference GlobeNewswire +11.02%
Jan-02-18 04:09PM  Breaking Down Diffusion Pharmaceuticals Incs (NASDAQ:DFFN) Ownership Structure Simply Wall St.
Dec-27-17 08:00AM  Diffusion Pharmaceuticals Begins Phase 3 Clinical Trial with TSC in Glioblastoma Multiforme GlobeNewswire +7.14%
Dec-19-17 01:35PM  Interested In Healthcare? Why Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) May Be The Entry Point Simply Wall St.
Dec-08-17 12:43PM  What You Must Know About Diffusion Pharmaceuticals Incs (DFFN) Risks Simply Wall St.
Nov-20-17 08:00AM  Diffusion Pharmaceuticals Regains Compliance with Nasdaq Capital Market Minimum Equity Rule GlobeNewswire
Nov-16-17 02:00PM  DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM Zacks Small Cap Research
Nov-13-17 08:00AM  Diffusion Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Oct-18-17 08:20AM  Today's Research Reports on Stocks to Watch: Neothetics, Inc. and Diffusion Pharmaceuticals ACCESSWIRE -15.46%
Oct-17-17 10:28AM  Diffusion Pharmaceuticals Inc to Initiate Phase 3 Trial in Inoperable GBM; Shares Soar 35% SmarterAnalyst +20.50%
07:30AM  Diffusion Pharmaceuticals Receives Final FDA Protocol Guidance for Phase 3 Clinical Trial with TSC in Patients Newly Diagnosed with Inoperable Glioblastoma Multiforme GlobeNewswire
Oct-10-17 10:00AM  Diffusion Pharmaceuticals to Present at the 2017 BIO Investor Forum GlobeNewswire
Sep-13-17 07:49PM  Is It The Right Time To Buy Diffusion Pharmaceuticals Inc (DFFN)? Simply Wall St. -5.03%
Sep-05-17 11:11AM  Diffusion Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-31-17 11:00AM  DFFN: Phase 3 Trial of TSC in GBM to Initiate Before End of 2017 Zacks Small Cap Research
Aug-23-17 07:30AM  Diffusion Pharmaceuticals Names William Hornung Chief Business Officer GlobeNewswire
Aug-14-17 04:01PM  Diffusion Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Jul-31-17 08:30AM  Diffusion Pharmaceuticals Selects Contract Research Organization for Phase 3 Clinical Trial of Lead Compound TSC for Inoperable GBM Brain Cancer GlobeNewswire
Jul-21-17 08:00AM  Today's Research Reports on Trending Tickers: Diffusion Pharmaceuticals Inc. and Juno Therapeutics Inc. Accesswire
Jul-20-17 08:30AM  Diffusion Pharmaceuticals Achieves Drug Production Milestone For Planned Phase 3 Clinical Trial In Inoperable GBM Brain Cancer GlobeNewswire
Jul-06-17 08:00AM  Diffusion Pharmaceuticals Appoints Dr. Robert Ruffolo to Board of Directors GlobeNewswire
May-26-17 10:00AM  Diffusion Pharmaceuticals to Present at the 7th Annual LD Micro Invitational Accesswire
May-25-17 12:00PM  DFFN: Focusing on Inoperable GBM Patients for Phase 3 Trial of TSC Zacks Small Cap Research
May-15-17 04:05PM  Diffusion Pharmaceuticals Provides Corporate Highlights and Reports Financial First Quarter 2017 Results GlobeNewswire
Apr-07-17 12:00PM  DFFN: Phase 3 Trial of TSC in GBM to Initiate in 2017 Zacks Small Cap Research
Apr-04-17 08:41AM  Diffusion Pharmaceuticals Awarded U.S. Patent for TSC as Therapeutic in Five Hypoxia-Related Indications GlobeNewswire
08:41AM  Diffusion Pharmaceuticals Awarded U.S. Patent for TSC as Therapeutic in Five Hypoxia-Related Indications
Apr-03-17 08:40AM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of E
08:30AM  Diffusion Pharmaceuticals Announces Closing of Oversubscribed Private Placement GlobeNewswire
Mar-31-17 04:25PM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
11:58AM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report
08:30AM  Diffusion Pharmaceuticals Provides Corporate Highlights and Reports 2016 Financial Results GlobeNewswire
Mar-29-17 09:30AM  Diffusion Pharmaceuticals Gets Professional Recognition and Akers Biosciences Achieves a First Accesswire
Mar-15-17 09:10AM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of E
Feb-08-17 11:35AM  Wednesdays Biggest Biopharma Movers 24/7 Wall St.
11:35AM  Wednesdays Biggest Biopharma Movers
08:00AM  Diffusion Pharmaceuticals TSC Phase 1/2 Glioblastoma Multiforme Clinical Trial Results Published in February 2017 Edition of Journal of Neurosurgery GlobeNewswire
Jan-27-17 06:14AM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K/A, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-26-17 03:52PM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, R
Jan-12-17 09:30AM  Latest Reports on Diffusion and Merrimack as Drug Stocks are Hit by President Trump's Comments Accesswire
Jan-10-17 10:42AM  This Small-Cap Rotation Is Unconvincing TheStreet.com
10:42AM  This Small-Cap Rotation Is Unconvincing
Jan-09-17 04:34PM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Dec-12-16 08:30AM  Diffusion Pharmaceuticals Files Definitive Proxy Statement for Upcoming Special Meeting of Stockholders GlobeNewswire
Nov-19-16 01:04PM  DIFFUSION PHARMACEUTICALS INC. Financials
Nov-14-16 11:30AM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
08:00AM  Diffusion Pharmaceuticals Provides Corporate Highlights and Reports Financial Third Quarter 2016 Results GlobeNewswire
Nov-08-16 11:02AM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
08:00AM  Diffusion Pharmaceuticals Announces Uplisting to NASDAQ Capital Market GlobeNewswire
Oct-13-16 04:45PM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an
Jun-08-16 06:07PM  Diffusion Pharmaceuticals, Inc. :DFFN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 Capital Cube
06:07PM  Diffusion Pharmaceuticals, Inc. :DFFN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016
May-31-16 11:45AM  DFFN: Initiating Coverage of Diffusion Pharmaceuticals: Lead Compound Entering Phase 3 Clinical Trial in Brain Cancer Zacks Small Cap Research
11:45AM  DFFN: Initiating Coverage of Diffusion Pharmaceuticals: Lead Compound Entering Phase 3 Clinical Trial in Brain Cancer
Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. was founded in 2001 and is headquartered in Charlottesville, Virginia.